髓系恶性肿瘤的固有免疫机制与免疫治疗
Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies.
作者信息
Small Sara, Numan Yazan, Platanias Leonidas C
机构信息
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
出版信息
Biomedicines. 2021 Nov 6;9(11):1631. doi: 10.3390/biomedicines9111631.
Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies. So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation. Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.
与其他癌症类似，髓系恶性肿瘤在其发展过程中被认为会颠覆免疫系统。这种颠覆通过恶性细胞自主和非自主机制发生，涉及对先天性和适应性免疫系统的操纵。目前正在研究多种策略来恢复、重定向或增强免疫系统，以对抗髓系恶性肿瘤。到目前为止，最成功的策略包括干扰素治疗和基于抗体的疗法，尽管嵌合抗原受体（CAR）细胞和免疫检查点抑制剂也是很有前景的疗法。在这篇综述中，我们讨论了针对髓系恶性肿瘤的固有免疫防御机制、目前已获批的药物以及正在研究的药物。总体而言，我们评估了免疫肿瘤学在治疗髓系恶性肿瘤方面的疗效和潜力。
Zotero 插件